Professor Melief to receive 2022 SITC Pedro J. Romero Award

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

ISA to Present at Business Conferences in May 2022

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress

ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)

ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy